MX388641B - Inhibidores heterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer. - Google Patents
Inhibidores heterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer.Info
- Publication number
- MX388641B MX388641B MX2017014584A MX2017014584A MX388641B MX 388641 B MX388641 B MX 388641B MX 2017014584 A MX2017014584 A MX 2017014584A MX 2017014584 A MX2017014584 A MX 2017014584A MX 388641 B MX388641 B MX 388641B
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- erk2
- erk1
- cancer treatment
- heterocyclic inhibitors
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 title 1
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 title 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 title 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 title 1
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 230000008482 dysregulation Effects 0.000 abstract 1
- 150000002391 heterocyclic compounds Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente solicitud proporciona nuevos compuestos heterocíclicos y sales farmacéuticamente aceptables de los mismos. También se proporcionan métodos para preparar estos compuestos. E stos compuestos son útiles para inhibir ERK1/2. Administrando a un paciente que necesita una cantidad terapéuticamente eficaz de uno o más de los compuestos de la fórmula (I), (ver Fórmula) en la que X, Y, Z, J, M y R1 a R8 se definen en la presente, estos compuestos son eficaces en el tratamiento de afecciones asociadas con la desregulación de la vía RAS/RAF/MEK/ERK. Se puede tratar una variedad de afecciones usando estos compuestos e incluyen enfermedades que se caracterizan por una proliferación celular anormal. En una modalidad, la enfermedad es cáncer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562175756P | 2015-06-15 | 2015-06-15 | |
| PCT/US2016/037697 WO2016205418A1 (en) | 2015-06-15 | 2016-06-15 | Heterocyclic inhibitors of erk1 and erk2 and their use in the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017014584A MX2017014584A (es) | 2018-02-26 |
| MX388641B true MX388641B (es) | 2025-03-20 |
Family
ID=56497830
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017014584A MX388641B (es) | 2015-06-15 | 2016-06-15 | Inhibidores heterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer. |
| MX2021000148A MX2021000148A (es) | 2015-06-15 | 2017-11-14 | Inhibidores eterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021000148A MX2021000148A (es) | 2015-06-15 | 2017-11-14 | Inhibidores eterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer. |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US9896445B2 (es) |
| EP (2) | EP3307727B1 (es) |
| JP (2) | JP6909729B2 (es) |
| KR (2) | KR102644788B1 (es) |
| CN (2) | CN107922387B (es) |
| AU (2) | AU2016280717C1 (es) |
| BR (1) | BR112017026159A2 (es) |
| CA (1) | CA2986587C (es) |
| DK (2) | DK3307727T3 (es) |
| ES (2) | ES2968007T3 (es) |
| FI (1) | FI3307727T3 (es) |
| IL (1) | IL255613B (es) |
| MX (2) | MX388641B (es) |
| PL (2) | PL3842429T3 (es) |
| PT (2) | PT3842429T (es) |
| RU (1) | RU2017139727A (es) |
| WO (1) | WO2016205418A1 (es) |
| ZA (1) | ZA201707526B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2986587C (en) * | 2015-06-15 | 2024-03-12 | Asana Biosciences, Llc | Heterocyclic inhibitors of erk1 and erk2 and their use in the treatment of cancer |
| US10457669B2 (en) | 2015-10-21 | 2019-10-29 | Otsuka Pharmaceutical Co., Ltd. | Benzolactam compounds as protein kinase inhibitors |
| GB201706327D0 (en) | 2017-04-20 | 2017-06-07 | Otsuka Pharma Co Ltd | A pharmaceutical compound |
| CN110799245B (zh) * | 2017-05-16 | 2022-08-09 | 生物医学谷探索股份有限公司 | 用于治疗具有非典型braf突变的癌症的组合物和方法 |
| AU2019280356B2 (en) * | 2018-06-08 | 2022-09-29 | Betta Pharmaceuticals Co., Ltd | ERK inhibitor and use thereof |
| CN109608444B (zh) * | 2018-11-27 | 2022-02-11 | 中国药科大学 | 含异吲哚啉酮的erk抑制剂及其制备方法与用途 |
| JP2022527744A (ja) | 2019-03-28 | 2022-06-06 | ジエンス ヘンルイ メデイシンカンパニー リミテッド | チエノ複素環式誘導体、この誘導体のための調製方法及び医療に関するこの誘導体の使用 |
| JP2022528083A (ja) * | 2019-03-29 | 2022-06-08 | ジエンス ヘンルイ メデイシンカンパニー リミテッド | ピロロ複素環式誘導体、この誘導体のための調製方法及び医学におけるこの誘導体の用途 |
| US20230027072A1 (en) * | 2019-10-28 | 2023-01-26 | Asana Biosciences, Llc | Improved methods, kits, compositions and dosing regimens for the use of heterocyclic inhibitors of erk1 and erk2 |
| CN111620860B (zh) * | 2020-06-23 | 2023-02-03 | 济南健丰化工有限公司 | 一种福瑞塞替的制备方法 |
| CN114315837B (zh) * | 2020-09-29 | 2023-06-16 | 江苏恒瑞医药股份有限公司 | 一种erk抑制剂的结晶形式及其制备方法 |
| JP2023543080A (ja) * | 2020-09-29 | 2023-10-12 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | ピロロ複素環系誘導体の結晶及びその製造方法 |
| US20240207269A1 (en) * | 2021-04-16 | 2024-06-27 | Erasca, Inc. | Uses of heterocyclic inhibitors of erk1/2 |
| WO2022271964A1 (en) * | 2021-06-24 | 2022-12-29 | Erasca, Inc. | Erk1/2 and shp2 inhibitors combination therapy |
| TW202317123A (zh) * | 2021-06-24 | 2023-05-01 | 美商艾瑞斯卡公司 | Erk1/2及cdk4/6抑制劑之組合療法 |
| KR20240049796A (ko) * | 2021-06-24 | 2024-04-17 | 에라스카, 아이엔씨. | Erk1/2 및 kras g12c 억제제 조합 요법 |
| WO2022271919A1 (en) * | 2021-06-24 | 2022-12-29 | Erasca, Inc. | Erk1/2 or shp2 inhibitors and flt3 inhibitors combination therapy |
| WO2023185869A1 (zh) * | 2022-03-28 | 2023-10-05 | 江苏恒瑞医药股份有限公司 | 一种吡咯并杂环类衍生物的富马酸盐的晶型及其制备方法 |
| WO2024064690A1 (en) * | 2022-09-20 | 2024-03-28 | Erasca, Inc. | Erk1/2 inhibitor polymorph forms |
| WO2024148307A1 (en) * | 2023-01-06 | 2024-07-11 | Erasca, Inc. | Raf inhibitor and erk1/2 and/or shp2 inhibitor combination therapy |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1319849B1 (it) | 2000-02-18 | 2003-11-03 | Angelo Dotta | Cerotto in confezione ad apertura rapida e mezzi per la realizzazionedella stessa. |
| MY130778A (en) * | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
| US6743941B2 (en) | 2001-06-15 | 2004-06-01 | Aventis Pharma Deutschland Gmbh | Process for the production of piperidine derivatives |
| US7279576B2 (en) | 2002-12-31 | 2007-10-09 | Deciphera Pharmaceuticals, Llc | Anti-cancer medicaments |
| US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
| WO2005068468A2 (en) | 2003-12-02 | 2005-07-28 | Vertex Pharmaceuticals, Inc. | Heterocyclic protein kinase inhibitors and uses thereof |
| US20070191336A1 (en) | 2003-12-24 | 2007-08-16 | Flynn Daniel L | Anti-inflammatory medicaments |
| ATE435858T1 (de) * | 2004-05-14 | 2009-07-15 | Vertex Pharma | Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen |
| US7501415B2 (en) * | 2004-12-23 | 2009-03-10 | Vertex Pharmaceuticals Incorporated | Selective inhibitors of ERK protein kinase and uses thereof |
| US8546404B2 (en) | 2005-12-13 | 2013-10-01 | Merck Sharp & Dohme | Compounds that are ERK inhibitors |
| EP2498607B1 (en) * | 2009-11-13 | 2016-02-17 | Genosco | Kinase inhibitors |
| WO2012142308A1 (en) | 2011-04-13 | 2012-10-18 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
| US9227969B2 (en) * | 2013-08-14 | 2016-01-05 | Novartis Ag | Compounds and compositions as inhibitors of MEK |
| CA2986587C (en) | 2015-06-15 | 2024-03-12 | Asana Biosciences, Llc | Heterocyclic inhibitors of erk1 and erk2 and their use in the treatment of cancer |
| EP3471717A4 (en) | 2016-06-20 | 2020-01-22 | Kura Oncology, Inc. | Treatment of squamous cell carcinomas with inhibitors of erk |
| TW202023556A (zh) | 2018-08-27 | 2020-07-01 | 美商庫拉腫瘤技術股份有限公司 | 以mapk路徑抑制劑治療腺癌 |
| US20230027072A1 (en) | 2019-10-28 | 2023-01-26 | Asana Biosciences, Llc | Improved methods, kits, compositions and dosing regimens for the use of heterocyclic inhibitors of erk1 and erk2 |
| US20240207269A1 (en) | 2021-04-16 | 2024-06-27 | Erasca, Inc. | Uses of heterocyclic inhibitors of erk1/2 |
-
2016
- 2016-06-15 CA CA2986587A patent/CA2986587C/en active Active
- 2016-06-15 BR BR112017026159-6A patent/BR112017026159A2/pt not_active Application Discontinuation
- 2016-06-15 KR KR1020177034157A patent/KR102644788B1/ko active Active
- 2016-06-15 PT PT211560487T patent/PT3842429T/pt unknown
- 2016-06-15 US US15/183,486 patent/US9896445B2/en active Active
- 2016-06-15 EP EP16741411.9A patent/EP3307727B1/en active Active
- 2016-06-15 PT PT167414119T patent/PT3307727T/pt unknown
- 2016-06-15 JP JP2017559575A patent/JP6909729B2/ja active Active
- 2016-06-15 DK DK16741411.9T patent/DK3307727T3/da active
- 2016-06-15 PL PL21156048.7T patent/PL3842429T3/pl unknown
- 2016-06-15 AU AU2016280717A patent/AU2016280717C1/en active Active
- 2016-06-15 KR KR1020217005104A patent/KR102644798B1/ko active Active
- 2016-06-15 WO PCT/US2016/037697 patent/WO2016205418A1/en not_active Ceased
- 2016-06-15 DK DK21156048.7T patent/DK3842429T3/da active
- 2016-06-15 MX MX2017014584A patent/MX388641B/es unknown
- 2016-06-15 ES ES16741411T patent/ES2968007T3/es active Active
- 2016-06-15 CN CN201680031963.5A patent/CN107922387B/zh active Active
- 2016-06-15 PL PL16741411.9T patent/PL3307727T3/pl unknown
- 2016-06-15 CN CN202110399513.4A patent/CN113200961B/zh active Active
- 2016-06-15 EP EP21156048.7A patent/EP3842429B1/en active Active
- 2016-06-15 US US15/183,504 patent/US10751332B2/en active Active
- 2016-06-15 ES ES21156048T patent/ES2930050T3/es active Active
- 2016-06-15 RU RU2017139727A patent/RU2017139727A/ru not_active Application Discontinuation
- 2016-06-15 FI FIEP16741411.9T patent/FI3307727T3/fi active
-
2017
- 2017-09-01 US US15/694,124 patent/US10471051B2/en active Active
- 2017-11-07 ZA ZA2017/07526A patent/ZA201707526B/en unknown
- 2017-11-12 IL IL255613A patent/IL255613B/en active IP Right Grant
- 2017-11-14 MX MX2021000148A patent/MX2021000148A/es unknown
-
2020
- 2020-02-13 US US16/790,082 patent/US11103491B2/en active Active
- 2020-11-19 AU AU2020273302A patent/AU2020273302B2/en active Active
-
2021
- 2021-03-16 JP JP2021042239A patent/JP7093438B2/ja active Active
- 2021-07-06 US US17/368,559 patent/US11925629B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX388641B (es) | Inhibidores heterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer. | |
| EA201790599A1 (ru) | Соединения и композиции в качестве ингибиторов киназ | |
| EA201890594A1 (ru) | Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний | |
| MX2017009571A (es) | Inhibidores heterociclicos de itk para el tratamiento de la inflamacion y cancer. | |
| ZA202001717B (en) | Compounds, salts thereof and methods for treatment of diseases | |
| MX390535B (es) | Compuestos de amino-triazolopiridina y su uso en el trataniento del cancer. | |
| NZ726366A (en) | Syk inhibitors | |
| EA201591610A1 (ru) | Ингибиторы кинуренинового пути | |
| MX391850B (es) | Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington | |
| PH12015502549A1 (en) | Heterocyclic derivatives | |
| MX2017016344A (es) | Compuestos de benzoxacepina oxazolidinona y metodos de uso. | |
| PE20180258A1 (es) | Inhibidores de bromodominio | |
| MX2021008610A (es) | Tratamiento del cancer usando combinaciones de inhibidores de erk y raf. | |
| MX2015014387A (es) | Quinazolinas y azaquinazolinas como inhibidores duales de vias ras/raf/mek/erk y pi3k/akt/pten/mtor. | |
| MX393057B (es) | Compuestos de indol carboxamida útiles como inhibidores de cinasas. | |
| EA201791576A1 (ru) | Ингибитор jak | |
| NZ736665A (en) | Heterocyclic amides as kinase inhibitors | |
| EA201591727A1 (ru) | Соединения биариламида в качестве ингибиторов киназы | |
| EA201690989A1 (ru) | Ингибиторы syk | |
| MX2018002889A (es) | Compuesto de pirimidina fusionada o sal del mismo. | |
| EA201792116A1 (ru) | Ингибитор янус-киназы | |
| EA201691151A1 (ru) | Соединения для лечения пациентов с ros1-мутантными раковыми клетками | |
| EA201591051A1 (ru) | Ингибиторы erk и варианты их применения | |
| MX386542B (es) | Derivados de la 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmacéuticas que los incluyen. | |
| WO2014141110A3 (en) | Aminonitriles as kynurenine pathway inhibitors |